Tiziana Life Sciences Ltd (NASDAQ:TLSA) Short Interest Up 20.5% in August

Tiziana Life Sciences Ltd (NASDAQ:TLSA) was the recipient of a large growth in short interest during the month of August. As of August 31st, there was short interest totaling 791,900 shares, a growth of 20.5% from the August 15th total of 657,200 shares. Currently, 1.3% of the company’s stock are short sold. Based on an average daily trading volume, of 345,800 shares, the short-interest ratio is currently 2.3 days. Based on an average daily trading volume, of 345,800 shares, the short-interest ratio is currently 2.3 days. Currently, 1.3% of the company’s stock are short sold.

Institutional Trading of Tiziana Life Sciences

A number of large investors have recently bought and sold shares of TLSA. Bison Wealth LLC acquired a new stake in Tiziana Life Sciences during the 4th quarter worth $30,000. Dauntless Investment Group LLC acquired a new stake in Tiziana Life Sciences during the 1st quarter worth $1,879,000. OMERS ADMINISTRATION Corp acquired a new stake in Tiziana Life Sciences during the 1st quarter worth $156,000. Cubist Systematic Strategies LLC acquired a new stake in Tiziana Life Sciences during the 1st quarter worth $25,000. Finally, Jane Street Group LLC boosted its stake in Tiziana Life Sciences by 968.2% during the 1st quarter. Jane Street Group LLC now owns 167,542 shares of the company’s stock worth $181,000 after purchasing an additional 151,858 shares during the period.

Tiziana Life Sciences Stock Up 7.2%

NASDAQ TLSA opened at $1.78 on Friday. The firm’s fifty day moving average price is $1.88 and its 200 day moving average price is $1.53. Tiziana Life Sciences has a 12 month low of $0.63 and a 12 month high of $2.60.

About Tiziana Life Sciences

Tiziana Life Sciences Ltd, a biotechnology company, focuses on the discovery and development of molecules to treat human diseases in oncology and immunology. The company's lead product candidate in immunology is Foralumab (TZLS-401), a human anti-CD3 monoclonal antibody (mAb) for the treatment of Crohn's, graft versus host, ulcerative colitis, multiple sclerosis, type-1 diabetes, inflammatory bowel, psoriasis, and rheumatoid arthritis diseases.